Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANQUILITY: TOUR006 in Chronic Kidney Disease
NCT06362759Phase 2Completed
- Sponsor
- Tourmaline Bio, Inc.
- Start
- May 2024
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pacibekitug in chronic kidney disease (CKD) (4 arms), sponsored by Tourmaline Bio, Inc. Primary endpoint: Time-Averaged Percent Change From Baseline in High-Sensitivity C-Reactive Protein at 90 days. Started May 2024; status: completed.
02
Drugs
pacibekitug
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06362759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06362759.